HP and mAbxience apply AI to optimize biosimilars production
Friday, 12 December 2025
HP SCDS alongside mAbxience have developed an artificial intelligence (AI)-based solution that optimizes the production of monoclonal antibodies and biosimilars, which are essential treatments for thousands of patients worldwide.
- Published in AI Lab, AI Solutions, Artificial Intelligence, Collaborations, Featured at home, HP, HP SCDS, Innovation, It's Happening